Marker Therapeutics (MRKR) Stock Rating Maintained at Buy by H.C. Wainwright

H.C. Wainwright has reiterated its buy rating for Marker Therapeutics (MRKR), affirming the stock's potential in the market. The report highlights Marker Therapeutics' ongoing efforts and pipeline developments, which indicate positive prospects for investors. Specific details about future performance or price targets were not disclosed, but the rating suggests confidence in the company's strategies. This confirmation could influence investor sentiment and trading activity around Marker Therapeutics, making it significant for market players.